尼日利亚东北部队列中接受多替拉韦方案治疗失败的经验性治疗者整合酶链转移抑制剂耐药有限出现:横断面分析
该研究对尼日利亚东北部61例多替拉韦方案病毒学失败者行全基因组测序,33例完整基因组分析显示,仅1例(HIV-1 G亚型)出现影响多替拉韦敏感性的耐药突变(T66A、G118R、E138K、R263K)。作者认为多替拉韦耐药率低,支持继续推广多替拉韦作为初治首选和转换二线首选,但需区域人群长期数据。
要点
- 33例完整基因组中仅1例(3%)检出影响多替拉韦敏感性的耐药突变。
- NRTI耐药突变17/33(52%),NNRTI耐药突变24/33(73%)。
- 作者认为数据支持继续推广多替拉韦作为初治首选及转换二线首选。
核心结论
- 本研究多替拉韦耐药率低,数据支持继续推广多替拉韦作为初治者一线方案及区域转换二线首选。
- 仍需区域人群层面长期多替拉韦结局数据以指导实施与政策。
研究设计与样本
- 横断面队列研究,纳入尼日利亚东北部61例多替拉韦方案病毒学失败者,采用Illumina平台对血浆样本行全基因组测序。
- 55例测序成功,质控后分析33例完整基因组,中位年龄40岁,中位抗逆转录病毒治疗时间9年。
- HIV-1亚型分析使用SNAPPy。
主要发现
- 多数参与者的突变谱反映既往暴露于含NRTI和NNRTI的一线和二线方案。
- NRTI耐药相关突变17/33(52%),NNRTI耐药相关突变24/33(73%)。
- 影响替诺福韦敏感性的耐药相关突变8/33(24.4%)。
- 仅1例HIV-1 G亚型感染者检出影响多替拉韦敏感性的耐药突变,为T66A、G118R、E138K和R263K。
临床怎么用
- 作者认为数据支持继续推广多替拉韦作为初治者一线方案及区域转换二线首选。
- 作者提出需区域人群层面长期多替拉韦结局数据以进一步指导实施与政策。
局限性
- 作者提出需区域人群层面长期多替拉韦结局数据以进一步指导实施与政策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Due to the high prevalence of resistance to NNRTI-based ART since 2018, consolidated recommendations from the WHO have indicated dolutegravir as the preferred drug of choice for HIV treatment globally. There is a paucity of resistance outcome data from HIV-1 non-B subtypes circulating across West Africa. AIMS: We characterized the mutational profiles of persons living with HIV from a cross-sectional cohort in North-East Nigeria failing a dolutegravir-based ART regimen. METHODS: WGS of plasma samples collected from 61 HIV-1-infected participants following virological failure of dolutegravir-based ART were sequenced using the Illumina platform. Sequencing was successfully completed for samples from 55 participants. Following quality control, 33 full genomes were analysed from participants with a median age of 40 years and median time on ART of 9 years. HIV-1 subtyping was performed using SNAPPy. RESULTS: Most participants had mutational profiles reflective of exposure to previous first- and second-line ART regimens comprised NRTIs and NNRTIs. More than half of participants had one or more drug resistance-associated mutations (DRMs) affecting susceptibility to NRTIs (17/33; 52%) and NNRTIs (24/33; 73%). Almost a quarter of participants (8/33; 24.4%) had one or more DRMs affecting tenofovir susceptibility. Only one participant, infected with HIV-1 subtype G, had evidence of DRMs affecting dolutegravir susceptibility-this was characterized by the T66A, G118R, E138K and R263K mutations. CONCLUSIONS: This study found a low prevalence of resistance to dolutegravir; the data are therefore supportive of the continual rollout of dolutegravir as the primary first-line regimen for ART-naive participants and the preferred switch to second-line ART across the region. However, population-level, longer-term data collection on dolutegravir outcomes are required to further guide implementation and policy action across the region.
引用
- Abdullahi A, Kida IM, Maina UA, et al. Limited emergence of resistance to integrase strand transfer inhibitors (INSTIs) in ART-experienced participants failing dolutegravir-based antiretroviral therapy: a cross-sectional analysis of a Northeast Nigerian cohort. J Antimicrob Chemother. 2023. PMID: 37367727. doi:10.1093/jac/dkad195
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。